Combination of dexamethasone and a somatostatin analogue in the treatment of advanced prostate cancer

Bibliography

• KOUTSILIERIS M, MITSIADES C, SOURLA A: Insulin-like growth factor I and urokinase-type plasminogen activator bioregulation system as a survival mechanism of prostate cancer cells in osteoblastic metastases: development of anti-survival factor therapy for hormone-refractory prostate cancer. Md. Med. (2000) 6:251–267.
   Google Scholar
• ••The role of IGFs/IGFBPs/uPA bioregulation system in the pathophysiology of osteoblastic metastasis.
   Google Scholar
• MITSIADES CS, KOUTSILIERIS M: Molecular biology and cellular physiology of refractoriness to androgen ablation therapy in advanced prostate cancer. Expert Opin. Itivestig. Drugs (2001) 10:1099–1115.
   PubMed Web of Science ®Google Scholar
• ••Pathophysiology of androgen refractorinessin osteoblastic lesions from metastatic prostate cancer.
   Google Scholar
• REYES-MORENO C, SOURLA A, CHOKI I et al.: Osteoblast-derived survival factors protect PC-3 human prostate cancer cells from adriamycin apoptosis. Urology (1998) 52:341–347.
   PubMed Web of Science ®Google Scholar
• ••Characterisation of the osteoblast-derivedsurvival factors and their role for the development of chemotherapy resistance in prostate cancer cells.
   Google Scholar
• KOUTSILIERIS M, POLYCHRONAKOS C: Proteinolytic activity against IGF-binding proteins involved in the paracrine interactions between prostate adenocarcinoma cells and osteoblasts. Anticancer Res. (1992) 12:905–910.
   PubMed Web of Science ®Google Scholar
• KOUTSILIERIS M, FRENETTE G, LAZURE C et al.: Urokinase-type plasminogen activator: a paracrine factor regulating the bioavailability of IGFs in PA-III cell-induced osteoblastic metastases. Anticancer Res. (1993) 13:481–486.
   PubMed Web of Science ®Google Scholar
• EZZAT S, REN SG, BRAUNSTEIN GD etal.: Octreotide stimulates insulin-like growth factor-binding protein-1: a potential pituitary-independent mechanism for drug action. j Clin. Endocrinol Metall. (1992) 75:1459–1463.
   Google Scholar
• DAVIES PH, STEWART SE, LANCRANJAN L et al: Long-term therapy with long-acting octreotide (Sandostatin-LAM for the management of acromegaly. Endocrinol (Ox!) (1998) 48:311–316.
   PubMed Web of Science ®Google Scholar
• •Long-term efficacy and efficiency of somatostatin analogues to control IGFs in acromegalic patients.
   Google Scholar
• KOUTSILIERIS M, DIMOPOULOS MA, DOILLON C etal.: The molecular concept of prostate cancer. Cancer J. (1996) 9:89–94.
   Web of Science ®Google Scholar
• KOUTSILIERIS M, FAURE N, TOLIS G et al.: Objective response and disease outcome in 59 patients with stage D2 prostatic cancer treated with either Buserelin or orchiectomy. Disease aggressivity and its association with response and outcome. Urology (1986) 27:221–228.
   Google Scholar
• KOUTSILIERIS M, LAROCHE B, THABET M et al.: The assessment of disease aggressivity in stage D2 prostate cancer patients (review). Anticancer Res. (1990) 10:333–336.
   PubMed Web of Science ®Google Scholar
• CRAWFORD ED, EISENBERGER MA, MCLEOD DG et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl. I Med. (1989) 321:419–424.
   PubMed Web of Science ®Google Scholar
• KOUTSILIERIS M: Osteoblastic metastasis in advanced prostate cancer. Anticancer Res. (1993) 13:443–449.
   PubMed Web of Science ®Google Scholar
• RAGHAVAN D, WALLACE M: Preemptive (neoadjuvant) chemotherapy: can analysis of eligibility criteria, prognostic factors, and tumor staging from different trials provide valid or useful comparisons? Semi]. Oncol. (1990) 17:613–618.
   Google Scholar
• TOLIS G, KOUTSILIERIS M, FAZEKAS AT et al: Transabdominal ultrasonography in the evaluation of patients with advanced prostatic carcinoma: effects of castration and of chronic administration of a gonadotropin releasing hormone agonistic analogue. Prostate (1983) 4:595–600.
   PubMed Web of Science ®Google Scholar
• BEHRAKIS P, KOUTSILIERIS M: Pulmonary metastases in metastatic prostate cancer: host tissue-tumor cell interactions and response to hormone therapy. Anticancer Res. (1997) 17:1517–1518.
   PubMed Web of Science ®Google Scholar
• TANNOCK IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? j Clin. Oncol (1985) 3:1013–1021.
   Google Scholar
• HUDES GR, GREENBERG R, KRIGEL RL et al.: Phase II study of estramustine and vinblastine, two microtubule inhibitors, in hormone-refractory prostate cancer. Oncol (1992) 10:1754–1761.
   Google Scholar
• HUDES G, EINHORN L, ROSS E et al: Vinblastine versus vinblastine plus oral estramustine phosphate for patients with hormone-refractory prostate cancer: a hoosier oncology group and fox chase network phase III trial. j Clin. Oncol (1999) 17:3160–3166.
   PubMed Web of Science ®Google Scholar
• POLYCHRONAKOS C, JANTHLY U, LEHOUX JG et al: Mitogenic effects of insulin and insulin-like growth factors on PA-III rat prostate adenocarcinoma cells: characterization of the receptors involved. Prostate (1991) 19:313–321.
   PubMed Web of Science ®Google Scholar
• MANTZOROS CS, TZONOU A, SIGNORELLO LB et al.: Insulin-like growth factor 1 in relation to prostate cancer and benign prostatic hyperplasia. Br I Cancer (1997) 76:1115–1118.
   PubMed Web of Science ®Google Scholar
• CHAN JM, STAMPFER MJ, GIOVANNUCCI E etal.: Plasma insulin-like growth factor-I and prostate cancer risk: a prospective study. Science (1998) 279:563–566.
   Google Scholar
• DELANY AM, CANALIS E: Transcriptional repression of insulin-like growth factor I by glucocorticoids in rat bone cells. Endocrinology (1995) 136:4776–4781.
   PubMed Web of Science ®Google Scholar
• •Glucocorticoid-mediated suppression of IGEs production in osteoblasts.
   Google Scholar
• REYES-MORENO C, KOUTSILIERIS M: Glucocorticoid receptor function possibly modulates cell-cell interactions in osteoblastic metastases on rat skeleton. Clin. Exp. Metastasis (1997) 15:205–217.
   PubMed Web of Science ®Google Scholar
• •Glucocorticoid-mediated inhibition of the prostate cancer cell -induced osteoblastic reaction in rat bone.
   Google Scholar
• REYES-MORENO C, FRENETTE G, BOULANGER J etal.: Mediation of glucocorticoid receptor function by transforming growth factor beta I expression in human PC-3 prostate cancer cells. Prostate (1995) 26:260–269.
   Google Scholar
• KOUTSILIERIS M: PA-III rat prostate adenocarcinoma cells (review). In Vivo (1992) 6:199–203.
   PubMedGoogle Scholar
• CHEN TL, MALLORY JB, HINTZ RL: Dexamethasone and 1,25(OH)2 vitamin D3 modulate the synthesis of insulin-like growth factor-I in osteoblast-like cells. CalciE Tissue Int. (1991) 48:278–282.
   PubMed Web of Science ®Google Scholar
• KOUTSILIERIS M, REYES-MORENO C, SOURLA A et al.: Growth factors mediate glucocorticoid receptor function and dexamethasone-induced regression of osteoblastic lesions in hormone refractory prostate cancer. Anticancer Res. (1997) 17:1461–1465.
   PubMed Web of Science ®Google Scholar
• RAJAH R, VALENTINIS B, COHEN P: Insulin-like growth factor (IGF)-binding protein-3 induces apoptosis and mediates the effects of transforming growth factor-betal on programmed cell death through a p53-and IGF-independent mechanism. I Biol. Chem. (1997) 272:12181–12188.
   Web of Science ®Google Scholar
• •IGFBP-3 mediated p53-independent apoptosis of cancer cells is produced by an IGF-independent mechanism.
   Google Scholar
• VILLAFUERTE BC, GOLDSTEIN S, ROBERTSON DG et al: Nutrition and somatomedin XXIX. Molecular regulation of IGFBP-1 in hepatocyte primary culture. Diabetes (1992) 41:835–842.
   Google Scholar
• GIUSTINA A, VELDHUIS JD: Pathophysiology of the neuroregulation of growth hormone secretion in experimental animals and the human. Endocr. Rev (1998) 19:717–797.
   PubMed Web of Science ®Google Scholar
• DUPONT A, GOMEZ JL, CUSAN L etal.: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. I Ural. (1993) 150:908–913.
   Google Scholar
• •Documentation of anti-androgen withdrawal syndrome in prostate cancer patients.
   Google Scholar
• KOUTSILIERIS M, TZANELA M, DIMOPOULOS T: Novel concept of antisurvival factor (ASF) therapy produces an objective clinical response in four patients with hormone-refractory prostate cancer: case report. Prostate (1999) 38:313–316.
   PubMed Web of Science ®Google Scholar
• KOUTSILIERIS M, MITSIADES C, DIMOPOULOS T et al.: A combination therapy of dexamethasone and somatostatin analog reintroduces objective clinical responses to LHRH analog in androgen ablation-refractory prostate cancer patients. Clin. Eric/arra Metab. (2001) 86:5729–5736.
   PubMed Web of Science ®Google Scholar
• ••Effectiveness of the ASF therapy(combination of dexamethasone plus somatostatin analogue) in the treatment of stage D3 prostate cancer patients.
   Google Scholar
• 34. SOLOWAY MS, HARDEMAN SW, HICKEY D et al.: Stratification of patients with metastatic prostate cancer based on extent of disease on initial bone scan. Cancer (1988) 61:195–202.
   Google Scholar
• PONDER BA, SHEARER RJ, POCOCK RD etal.: Response to aminoglutethimide and cortisone acetate in advanced prostatic cancer. Br. J. Cancer (1984) 50:757–763.
   Google Scholar
• PLOWMAN PN, PERRY LA, CHARD T: Androgen suppression by hydrocortisone without aminoglutethimide in orchiectomised men with prostatic cancer. Br Ural. (1987) 59:255–257.
   PubMedGoogle Scholar
• MANNI A, SANTEN RJ, BOUCHER AE et al.: Androgen depletion and repletion as a means of potentiating the effect of cytotoxic chemotherapy in advanced prostate cancer. Steroid Biochem. (1987) 27:551–556.
   PubMedGoogle Scholar
• ELOMAA I, TAUBE T, BLOMQVIST C et al.: Aminoglutethimide for advanced prostatic cancer resistant to conventional hormonal therapy. Eur. Ural. (1988) 14:104–106.
   PubMed Web of Science ®Google Scholar
• LABRIE F, DUPONT A, BELANGER A et al.: Anti-hormone treatment for prostate cancer relapsing after treatment with flutamide and castration. Addition of aminoglutethimide and low dose hydrocortisone to combination therapy. Br Ural. (1989) 63:634–638.
   Google Scholar
• HELLMANN K, PHILLIPS RH, GO OLD M: High dose dexamethasone and base of brain irradiation for hormone refractory metastatic carcinoma of the prostate. Chu. Exp. Metastasis (1993) 11:227–229.
   PubMed Web of Science ®Google Scholar
• KELLY WK, SCHER HI, MAZUMDAR M et al.: Suramin and hydrocortisone: determining drug efficacy in androgen-independent prostate cancer. I Clin. Oricol (1995) 13:2214–2222.
   PubMed Web of Science ®Google Scholar
• STORLIE JA, BUCKNER JC, WISEMAN GA etal.: Prostate specific antigen levels and clinical response to low dose dexamethasone for hormone-refractory metastatic prostate carcinoma. Cancer (1995) 76:96–100.
   Google Scholar
• ENOMOTO Y, FUKUHARA H, KURIMOTO S et al.: [A case of hormone-refractory prostate cancer responsive to low-dose prednisolone therapy]. Nippon Hirryokika Cakkai Zasshi (1997) 88:636–639.
   PubMedGoogle Scholar
• FIGG WD, KROOG G, DURAY P et al: Flutamide withdrawal plus hydrocortisone resulted in clinical complete response in a patient with prostate carcinoma. Cancer (1997) 79:1964–1968.
   PubMed Web of Science ®Google Scholar
• SMALL EJ, BARON A, BOK R: Simultaneous antiandrogen withdrawal and treatment with ketoconazole and hydrocortisone in patients with advanced prostate carcinoma. Cancer (1997) 80:1755–1759.
   PubMed Web of Science ®Google Scholar
• NISHIMURA K, NONOMURA N, YASUNAGA Y etal.: Low doses of oral dexamethasone for hormone-refractory prostate carcinoma. Cancer (2000) 89:2570–2576.
   Google Scholar
• •Therapeutic role of glucocorticoid administration in hormone refractory prostate cancer patients.
   Google Scholar
• SARTOR 0, WEINBERGER M, MOORE A etal.: Effect of prednisone on prostate-specific antigen in patients with hormone-refractory prostate cancer. Urology (1998) 52:252–256.
   Google Scholar
• SINISI AA, BELLASTELLA A, PREZIOSOD et al.: Different expression patterns of somatostatin receptor subtypes in cultured epithelial cells from human normal prostate and prostate cancer. I Chu. Endocrirrol Metab. (1997) 82:2566–2569.
   PubMed Web of Science ®Google Scholar
• BREVINI TA, BIANCHI R, MOTTA M: Direct inhibitory effect of somatostatin on the growth of the human prostatic cancer cell line LNCaP: possible mechanism of action. Eridocrinol. Metab. (1993) 77:626–631.
   Google Scholar
• KOPPAN M, NAGY A, SCHALLY AV et al.: Targeted cytotoxic analogue of somatostatin AN-238 inhibits growth of androgen-independent Dunning R-3327-AT-1 prostate cancer in rats at nontoxic doses. Cancer Res. (1998) 58:4132–4137.
   PubMed Web of Science ®Google Scholar
• NAGY A, SCHALLY AV, HALMOS G et al.: Synthesis and biological evaluation of cytotoxic analogs of somatostatin containing doxorubicin or its intensely potent derivative, 2-pyrrolinodoxorubicin. Proc. Natl. Acad. Li. USA (1998) 95:1794–1799.
   PubMed Web of Science ®Google Scholar
• FIGG WD, THIBAULT A, COOPER MR et al.: A phase I study of the somatostatin analogue somatuline in patients with metastatic hormone-refractory prostate cancer. Cancer (1995) 75:2159–2164.
   PubMed Web of Science ®Google Scholar
• MAULARD C, RICHAUD E DROZ JP et al.: Phase I-II study of the somatostatin analogue lanreotide in hormone- refractory prostate cancer. Cancer Chernother. Phannacol (1995) 36:259–262.
   Google Scholar
• VAINAS G, PASAITOU V, GALAKTIDOUG et al.: The role of somatostatin analogues in complete antiandrogen treatment in patients with prostatic carcinoma. j Exp. Clin. Cancer. Res. (1997) 16:119–126.
   PubMed Web of Science ®Google Scholar
• •The combined use of somatostatin analogues with androgen ablation therapy in stage D2 prostate cancer patients.
   Google Scholar
• CALIGARIS-CAPPIO F, BERGUI L, GREGORETTI MG et al: 'Role of bone marrow stromal cells in the growth of human multiple myeloma. Blood (1991) 77:2688–2693.
   PubMed Web of Science ®Google Scholar
• TREON SP, ANDERSON KC: Interleukin-6 in multiple myeloma and related plasma cell dyscrasias. Cum: Opiri. Hernatol (1998) 5:42–48.
   Google Scholar
• BATAILLE R, CHAPPARD D, MARCELLI C et al.: Recruitment of new osteoblasts and osteoclasts is the earliest critical event in the pathogenesis of human multiple myeloma. I Clin. Invest. (1991) 88:62–66.
   PubMed Web of Science ®Google Scholar
• CALIGARIS-CAPPIO E GREGORETTI MG, GHIA P et al: In vitro growth of human multiple myeloma: implications for biology and therapy. Hematol Oncol North Am. (1992) 6:257–271.
   PubMed Web of Science ®Google Scholar
• BORSELLINO N, BELLDEGRUN A, BONAVIDA B: Endogenous interleukin 6 is a resistance factor for cis-diamminedichloroplatinum and etoposide-mediated cytotoxicity of human prostate carcinoma cell lines. Cancer Res. (1995) 55:4633–4639.
   PubMed Web of Science ®Google Scholar
• ••The role of IL-6 as survival factor forprostate cancer cells.
   Google Scholar
• DRACHENBERG DE, ELGAMAL AA, ROWBOTHAM R et al: Circulating levels of interleukin-6 in patients with hormone refractory prostate cancer. Prostate (1999) 41:127–133.
   PubMed Web of Science ®Google Scholar
• MANOLAGAS SC: The role of IL-6 type cytokines and their receptors in bone. Ann. NY Acad. Li. (1998) 840:194–204.
   PubMed Web of Science ®Google Scholar
• SWOLIN-EIDE D, OHLSSON C: Effects of cortisol on the expression of interleukin-6 and interleukin- 1 beta in human osteoblast-like cells. j Endocrinol. (1998) 156:107–114.
   PubMed Web of Science ®Google Scholar
• HIERL T, BORCSOK I, SOMMER U eta/.: Regulation of interleukin-6 expression in human osteoblastic cells in vitro. Exp. an. Eric/0mila Diabetes (1998) 106:324–333.
   Google Scholar
• SONGS, WIENTJES MG, GAN Y et al: Fibroblast growth factors: an epigenetic mechanism of broad spectrum resistance to anticancer drugs. Proc. Natl. Acad. Sci. USA (2000) 97:8658–8663.
   PubMed Web of Science ®Google Scholar
• MEYER GE, YU E, SIEGAL JA et al: Serum basic fibroblast growth factor in men with and without prostate carcinoma. Cancer (1995) 76:2304–2311.
   PubMed Web of Science ®Google Scholar
• CRONAUER MV, HITTMAIR A, EDER IE et al.: Basic fibroblast growth factor levels in cancer cells and in sera of patients suffering from proliferative disorders of the prostate. Prostate (1997) 31:223–233.
   PubMed Web of Science ®Google Scholar
• ••The role of bFGF as survival factor forprostate cancer cells.
   Google Scholar
• DI RAIMONDO E AZZARO MP, PALUMBO G etal.: Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Hatinatologica (2000) 85:800–805.
   Google Scholar
• CLEUTJENS CB, STEKETEE K, VAN EEKELEN CC et al.: Both androgen receptor and glucocorticoid receptor are able to induce prostate-specific antigen expression, but differ in their growth-stimulating properties of LNCaP cells. Endocrinology (1997) 138:5293–5300.
   Google Scholar
• SHAN JD, PORVARI K, RUOKONEN M et al.: Steroid-involved transcriptional regulation of human genes encoding prostatic acid phosphatase, prostate-specific antigen, and prostate- specific glandular kallikrein. Endocrinology (1997) 138:3764–3770.
   PubMed Web of Science ®Google Scholar
• YOUNG CY, MONTGOMERY BT, ANDREWS PE et al.: Hormonal regulation of prostate-specific antigen messenger RNA in human prostatic adenocarcinoma cell line LNCaP. Cancer Res. (1991) 51:3748–3752.
   PubMed Web of Science ®Google Scholar
• MONTGOMERY BT, YOUNG CY, BILHARTZ DL et al.: Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate (1992) 21:63–73.
   PubMedGoogle Scholar